Cardiovascular and Renal Drugs Advisory Committee
Committee Meeting March 27, 2012 8:00 a.m. to 5:00 p.m.
Agenda: On March 27, 2012, from 11:00 a.m. to 5:00 p.m. the committee will discuss biologics license application (BLA) 125410, proposed tradename REPLAGAL (agalsidase alfa), submitted by Shire Human Genetics Therapies, for an enzyme replacement therapy (ERT) for patients with Fabry disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment